New phase 3 data from the OPTIMUM head-to-head trial show that 20-mg ponesimod resulted in a significantly lower annualized relapse rate in adults with multiple sclerosis compared to 14-mg teriflunomide at 108 weeks.
Neurology News Network for the week ending September 7, 2019.

SAP Partner Banner

About NeurologyLive's Multiple Sclerosis Clinical Focus page:

The NeurologyLive Multiple Sclerosis Clinical Focus center offers the latest clinical news and expert insights related to this disabling disease of the central nervous system (CNS). Content found here includes video interviews with multiple sclerosis experts and key opinion leaders in neurology sharing insights on new and emerging therapies and management techniques, including insight and perspective novel treatment techniques. 

This page offers information regarding current strategies for multiple sclerosis treatment, as well as emerging therapeutic options for the disease being presented at major medical conferences and gaining traction in the scientific literature.